1 / 4

North American Inflammatory Bowel Disease (IBD) Therapeutics Market

The North American IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.8% during the forecast period.

globalomr
Télécharger la présentation

North American Inflammatory Bowel Disease (IBD) Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research North Therapeutics Market: Analysis Report, Share, Trends and Overview 2021-2027 American Inflammatory Bowel Disease (IBD) Request a free sample of our report on North American Inflammatory Bowel Disease (IBD) Therapeutics Market: https://www.omrglobal.com/request-sample/north-american-ibd- inflammatory-bowel-disease-therapeutics-market ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404

  2. The North American IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.8% during the forecast period. Rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in the US and significant funding in the IBD field in Canada is further estimated to boost the market growth of the region. Furthermore, well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across the region will support the market growth over the forecast period. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per Crohn's and Colitis Canada (CCC), in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians have IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population. A full report of North American Inflammatory Bowel Disease (IBD) Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/north-american-ibd-inflammatory-bowel-disease- therapeutics-market North American IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD. To learn more about this report request a sample copy @ https://www.omrglobal.com/request- sample/north-american-ibd-inflammatory-bowel-disease-therapeutics-market The companies which are contributing to the growth of the North American IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

  3. North American Inflammatory Bowel Disease (IBD) Therapeutics Market- Segmentation By Disease Type Ulcerative Colitis Crohn’s Disease By Treatment Type Surgery Anti- Inflammatory Drug Administration For more customized data, request for report customization @ https://www.omrglobal.com/report- customization/north-american-ibd-inflammatory-bowel-disease-therapeutics-market North American Inflammatory Bowel Disease (IBD) Therapeutics Market– Segment by Region United States Canada Company Profiles Abbott Laboratories AbbVie Inc. Boehringer Ingelheim International GmbH Celgene Corp. Eli Lilly and Co. Johnson & Johnson Services Inc. Laboratory Corporation of America Holdings Pfizer Inc. Sanofi S.A. Takeda pharmaceutical Co., Ltd. Reasons to Buying From us – 1.We cover more than 15 major industries, further segmented into more than 90 sectors. 2.More than 120 countries are for analysis. 3.Over 100+ paid data sources mined for investigation. 4.Our expert research analysts answer all your questions before and after purchasing your report.

  4. About Orion Market Research OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404

More Related